CytoDyn

CytoDyn is a clinical-stage biotech focused on developing its sole asset, the CCR5-targeting monoclonal antibody leronlimab, primarily for solid-tumor oncology. The company has pivoted from earlier efforts in HIV and COVID-19 to concentrate on oncology, citing promising long-term survival data in metastatic breast cancer. Its strategy hinges on positioning leronlimab as a 'prime-and-pair' agent to sensitize 'cold' tumors to immune checkpoint inhibitors, while concurrently advancing a broad preclinical pipeline across multiple cancer types and inflammatory diseases.

A platform centered on the CCR5 receptor and its proprietary humanized monoclonal antibody inhibitor, leronlimab, being developed as a 'platform drug' across multiple indications, primarily in solid-tumor oncology.